DNA 拓扑异构酶 I 抑制剂与肺癌放疗
DNA topoisomerase I drugs and radiotherapy for lung cancer.
出版信息
J Thorac Dis. 2012 Aug;4(4):390-7. doi: 10.3978/j.issn.2072-1439.2012.07.12.
Abstract
Lung cancer represents the most common cause of cancer-related mortality in the United States and around the world. DNA topoisomerase I (TOP1) drugs such as irinotecan and topotecan represent a unique class of chemotherapeutic agents that exhibit not only potent cytotoxic effect, but also tumor-selective radiation-sensitizing effect. The mechanism of cytotoxicity and radiation sensitization by TOP1 drugs has been intensely investigated. Modern radiotherapy, aided by improved imaging and treatment delivery technology, is capable of targeting tumors more precisely, while sparing surrounding critical structures. Clinical trials with camptothecin derivatives and radiotherapy have been conducted in lung cancers. Combined modality therapy with TOP1 drugs and radiotherapy offers a new frontier for lung cancer therapy. We review the present state of TOP1-targeted chemotherapy and modern radiotherapy for lung cancer.
摘要
肺癌是美国和全球癌症相关死亡的最常见原因。DNA 拓扑异构酶 I（TOP1）药物，如伊立替康和拓扑替康，代表了一类独特的化疗药物，不仅具有强大的细胞毒性作用，而且具有肿瘤选择性的放射增敏作用。TOP1 药物的细胞毒性和放射增敏作用的机制已被深入研究。现代放疗借助改进的成像和治疗输送技术，能够更精确地靶向肿瘤，同时保护周围的关键结构。喜树碱衍生物与放疗联合治疗肺癌的临床试验已经开展。TOP1 药物与放疗联合的综合治疗为肺癌治疗提供了新的前沿领域。我们综述了肺癌的 TOP1 靶向化疗和现代放疗的现状。
相似文献
1
DNA topoisomerase I drugs and radiotherapy for lung cancer.DNA 拓扑异构酶 I 抑制剂与肺癌放疗
J Thorac Dis. 2012 Aug;4(4):390-7. doi: 10.3978/j.issn.2072-1439.2012.07.12.
2
Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs.使用靶向DNA拓扑异构酶I的药物增强放射治疗
Crit Rev Oncol Hematol. 2004 May;50(2):111-9. doi: 10.1016/j.critrevonc.2003.09.005.
3
Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer.
Mol Cancer Ther. 2005 Feb;4(2):317-24.
4
Topoisomerase I inhibitors in the combined-modality therapy of lung cancer.拓扑异构酶I抑制剂在肺癌综合治疗中的应用
Oncology (Williston Park). 2004 Jun;18(7 Suppl 4):29-39.
5
Topoisomerase I inhibitors in the combined modality therapy of lung cancer.
Clin Lung Cancer. 2001 May;2 Suppl 2:S34-40. doi: 10.3816/clc.2001.s.006.
6
DNA topoisomerase I-targeting drugs as radiation sensitizers.靶向DNA拓扑异构酶I的药物作为辐射增敏剂
Oncology (Williston Park). 1999 Oct;13(10 Suppl 5):39-46.
7
Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity?拓扑异构酶I（Top1）：FL118抗肿瘤疗效的主要靶点还是主要涉及其造血毒性的副作用？
Am J Cancer Res. 2017 Feb 1;7(2):370-382. eCollection 2017.
8
Mechanisms of resistance to topoisomerase I-targeting drugs.对靶向拓扑异构酶I药物的耐药机制。
Oncogene. 2003 Oct 20;22(47):7296-304. doi: 10.1038/sj.onc.1206935.
9
Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.铂化DNA加合物增强喜树碱对DNA拓扑异构酶I的毒害作用。
J Biol Chem. 2004 Dec 24;279(52):54502-9. doi: 10.1074/jbc.M410103200. Epub 2004 Oct 6.
10
Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.拓扑异构酶降解、双链断裂修复、p53与IAPs在癌细胞对喜树碱类拓扑异构酶I抑制剂耐药中的作用
Biochim Biophys Acta. 2013 Jan;1835(1):11-27. doi: 10.1016/j.bbcan.2012.09.002. Epub 2012 Sep 21.
引用本文的文献
1
Consensus recommendations regarding local and metastasis-directed therapies in the management of relapsed/recurrent Ewing sarcoma.关于复发性/转移性尤因肉瘤治疗中局部和转移导向治疗的共识性建议。
Cancer. 2025 May 1;131(9):e35858. doi: 10.1002/cncr.35858.
2
Dual Topoisomerase Inhibitor Is Highly Potent and Improves Antitumor Response to Radiotherapy in Cervical Carcinoma.双拓扑异构酶抑制剂具有高效能，并能改善宫颈癌对放疗的抗肿瘤反应。
Int J Mol Sci. 2025 Mar 21;26(7):2829. doi: 10.3390/ijms26072829.
3
Topoisomerase I Inhibition Radiosensitizing Hepatocellular Carcinoma by RNF144A-mediated DNA-PKcs Ubiquitination and Natural Killer Cell Cytotoxicity.拓扑异构酶I抑制通过RNF144A介导的DNA-PKcs泛素化和自然杀伤细胞细胞毒性使肝细胞癌对放疗增敏
J Clin Transl Hepatol. 2023 Jun 28;11(3):614-625. doi: 10.14218/JCTH.2022.00271. Epub 2023 Jan 4.
4
A Proposed Trial Design for the Treatment of Widely Metastatic Ewing Sarcoma Inspired by Evolutionary Dynamics.受进化动力学启发的广泛转移性尤因肉瘤治疗试验设计方案
Cancers (Basel). 2022 Jan 31;14(3):736. doi: 10.3390/cancers14030736.
5
Integration of gene co-expression analysis and multi-class SVM specifies the functional players involved in determining the fate of HTLV-1 infection toward the development of cancer (ATLL) or neurological disorder (HAM/TSP).基因共表达分析和多类 SVM 的整合，明确了决定 HTLV-1 感染向癌症（ATLL）或神经紊乱（HAM/TSP）发展的命运的功能参与者。
PLoS One. 2022 Jan 18;17(1):e0262739. doi: 10.1371/journal.pone.0262739. eCollection 2022.
6
Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells (HSPCs) with TOP1-targeted drugs and PARP1 inhibitors.用 TOP1 靶向药物和 PARP1 抑制剂对 TET2 突变的造血干细胞和祖细胞（HSPCs）进行合成致死靶向治疗。
Leukemia. 2020 Nov;34(11):2992-3006. doi: 10.1038/s41375-020-0927-5. Epub 2020 Jun 22.
7
Selective Inhibition of Escherichia coli RNA and DNA Topoisomerase I by Hoechst 33258 Derived Mono- and Bisbenzimidazoles.吖啶类染料单苯并咪唑及双苯并咪唑衍生物对大肠埃希菌 RNA 和 DNA 拓扑异构酶 I 的选择性抑制作用。
J Med Chem. 2017 Jun 22;60(12):4904-4922. doi: 10.1021/acs.jmedchem.7b00191. Epub 2017 May 31.
8
Xanthohumol induces apoptosis and S phase cell cycle arrest in A549 non-small cell lung cancer cells.黄腐酚可诱导A549非小细胞肺癌细胞凋亡并使其细胞周期停滞于S期。
Pharmacogn Mag. 2015 Oct;11(Suppl 2):S275-83. doi: 10.4103/0973-1296.166069.
9
Synergistic efficacy of γ-radiation together with gallium trichloride and/or doxorubicin against Ehrlich carcinoma in female mice.γ射线联合三氯化镓和/或阿霉素对雌性小鼠艾氏癌的协同疗效。
Tumour Biol. 2016 Feb;37(2):1825-34. doi: 10.1007/s13277-015-3954-5. Epub 2015 Aug 29.
10
The Impact of Hedgehog Signaling Pathway on DNA Repair Mechanisms in Human Cancer. Hedgehog 信号通路对人类癌症中 DNA 修复机制的影响。
Cancers (Basel). 2015 Jul 21;7(3):1333-48. doi: 10.3390/cancers7030839.
本文引用的文献
1
A millimeter miss is as good as a thousand miles: The role of accurate target localization in lung stereotactic body radiation therapy.差之毫厘，谬以千里：精确靶区定位在肺部立体定向体部放射治疗中的作用。
J Thorac Dis. 2012 Apr 1;4(2):109-11. doi: 10.3978/j.issn.2072-1439.2012.03.12.
2
Central-airway necrosis after stereotactic body-radiation therapy.立体定向体部放射治疗后中央气道坏死
N Engl J Med. 2012 Jun 14;366(24):2327-9. doi: 10.1056/NEJMc1203770.
3
Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data.药物能否增强超分割放射治疗？一种使用体外数据模拟放射增敏作用的新方法。
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):385-93. doi: 10.1016/j.ijrobp.2011.06.1990. Epub 2012 Jan 19.
4
Cancer statistics, 2012.癌症统计数据，2012 年。
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
5
Non-small-cell lung cancer.非小细胞肺癌。
Lancet. 2011 Nov 12;378(9804):1727-40. doi: 10.1016/S0140-6736(10)62101-0. Epub 2011 May 10.
6
Small-cell lung cancer.小细胞肺癌。
Lancet. 2011 Nov 12;378(9804):1741-55. doi: 10.1016/S0140-6736(11)60165-7. Epub 2011 May 10.
7
A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706.一项 II 期研究，评估顺铂和伊立替康作为诱导化疗，随后联合每周低剂量伊立替康胸部放疗，用于不可切除的 IIIB 期非小细胞肺癌：JCOG 9706。
Jpn J Clin Oncol. 2011 Jan;41(1):25-31. doi: 10.1093/jjco/hyq163. Epub 2010 Aug 27.
8
A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.一项比较伊立替康/铂类与依托泊苷/铂类在未经治疗的广泛期小细胞肺癌患者中的随机对照试验的荟萃分析。
J Thorac Oncol. 2010 Jun;5(6):867-73. doi: 10.1097/jto.0b013e3181d95c87.
9
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.伊立替康/顺铂与依托泊苷/顺铂治疗广泛期小细胞肺癌的III期试验：SWOG S0124的临床和药物基因组学结果
J Clin Oncol. 2009 May 20;27(15):2530-5. doi: 10.1200/JCO.2008.20.1061. Epub 2009 Apr 6.
10
Chemotherapy for brain metastases in small-cell lung cancer.
Clin Lung Cancer. 2008 Jan;9(1):35-8. doi: 10.3816/CLC.2008.n.006.
Zotero 插件